BACKGROUND: @entity694 with @entity2198 have clinical and pathological features that distinguish them from @entity5 . We investigated the usefulness of @entity124 status as a predictor of the benefit of adjuvant chemotherapy with @entity1487 in @entity5 . METHODS: Tumor specimens were collected from @entity1 with @entity694 who were enrolled in randomized trials of @entity1487 -based adjuvant chemotherapy. Microsatellite instability was assessed with the use of @entity20133 and dinucleotide markers. RESULTS: Of 570 tissue specimens, 95 (16.7 percent) exhibited @entity2198 . Among 287 @entity1 who did not receive adjuvant therapy, those with @entity5 displaying @entity2198 had a better five-year rate of overall survival than @entity1 with @entity5 exhibiting microsatellite stability or low-frequency instability (hazard ratio for @entity204 , 0.31 [95 percent confidence interval, 0.14 to 0.72]; P=0.004). Among @entity1 who received adjuvant chemotherapy, @entity2198 was not correlated with increased overall survival (hazard ratio for @entity204 , 1.07 [95 percent confidence interval, 0.62 to 1.86]; P=0.80). The benefit of treatment differed significantly according to the @entity124 status (P=0.01). Adjuvant chemotherapy improved overall survival among @entity1 with @entity5 or @entity5 exhibiting @entity4365 instability, according to a multivariate analysis adjusted for stage and grade (hazard ratio for @entity204 , 0.72 [95 percent confidence interval, 0.53 to 0.99]; P=0.04). By contrast, there was no benefit of adjuvant chemotherapy in the group with @entity2198 . CONCLUSIONS: @entity1487 -based adjuvant chemotherapy benefited @entity1 with @entity5 with @entity5 or @entity5 exhibiting @entity4365 instability but not those with @entity5 exhibiting @entity2198 .

Tumor @entity124 status as a predictor of benefit from @entity1487 -based adjuvant chemotherapy for XXXX .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity2198 :: ('MESH:D006316', 'Disease') :: ['high-frequency microsatellite instability'] @entity124 :: ('MESH:D053842', 'Disease') :: ['microsatellite-instability'] @entity5 :: ('MESH:D009369', 'Disease') :: ['stage II and stage III colon cancer', 'stage II or stage III colon cancer', 'microsatellite-stable tumors', 'tumors'] @entity20133 :: ('CHEBI:29075', 'Chemical') :: ['mononucleotide'] @entity4365 :: ('MESH:C565121', 'Disease') :: ['low-frequency microsatellite'] @entity694 :: ('MESH:D003110', 'Disease') :: ['colon cancer', 'Colon cancers'] @entity204 :: ('MESH:D003643', 'Disease') :: ['death'] @entity1487 :: ('MESH:D005472', 'Chemical') :: ['fluorouracil', 'Fluorouracil']
@entity694 :: (MESH:D003110,Disease) :: ['colon cancer']
